中文 | English
Return
Total: 17 , 1/2
Show Home Prev Next End page: GO
Author:(Shengnan DU)

1.Clinical features and serum lipidomic profile of patients with nonalcoholic fatty liver disease and healthy individuals in the overweight population

Xiaoyan CHEN ; Yifu YUAN ; Shengnan DU ; Qin CAO ; Yuanye JIANG

Journal of Clinical Hepatology 2024;40(2):284-291

2.The effects of gambogenic acid on proliferation and apoptosis of CAL27 cell xenograft tumor in nude mice

Chen DU ; Shengnan LI ; Yuxin CHEN ; Zhiming XU ; Xinran LI ; Bin CHEN ; Jian MENG

Journal of Practical Stomatology 2024;40(2):216-221

3.Effects of transcranial magneto-acoustical stimulation on beta oscillations in neural circuits of healthy and Parkinson's disease rats

Shuai ZHANG ; Shengnan YOU ; Wenjing DU ; Lei WANG ; Guizhi XU

Chinese Journal of Tissue Engineering Research 2024;28(16):2519-2526

4.Duration of second stage of labor and its association with pregnancy outcome

Tianying ZHU ; Junnan MA ; Xiaohong LI ; Mingfang WANG ; Mingyu DU ; Shengnan YU ; Dajin LIU ; Runmei MA

Chinese Journal of Perinatal Medicine 2023;26(3):186-193

5.Quality evaluation of Crataegus pinnatifida leaves by fingerprint combined with quantitative analysis of multi-components by single-marker

Yanrong LI ; Liying DUAN ; Hong WEI ; Yilong DU ; Shengnan ZHAO ; Han GAO ; Haifeng PAN

China Pharmacy 2023;34(22):2727-2733

6.Iron isomaltoside for the treatment of iron deficiency anemia:a rapid health technology assessment

Xuting LIU ; Shengnan GAO ; Ran QI ; Guiping DU ; Guoqiang LIU

China Pharmacy 2022;33(24):3040-3044

7.Cost-utility analysis of denosumab and zoledronic acid in the treatment of postmenopausal osteoporosis

Guiping DU ; Shengnan GAO ; Ran QI ; Xuting LIU ; Guoqiang LIU

China Pharmacy 2022;33(14):1742-1747

8.Cost-utility analysis of durvalumab for consolidation therapy after chemoradiotherapy for stage Ⅲ non-small cell lung cancer

Jian SHI ; Ran QI ; Shengnan GAO ; Xuting LIU ; Guiping DU ; Guoqiang LIU

China Pharmacy 2022;33(15):1860-1864

9.Quality evaluation of Xin ’an capsules by combination of fingerprint ,multi-component quantitative analysis and chemical pattern recognition analysis

Yanrong LI ; Yilong DU ; Ying SHEN ; Zhe WU ; Dixin WANG ; Shengnan ZHAO ; Haifeng PAN

China Pharmacy 2022;33(6):706-712

10.Cost-utility analysis of pembrolizumab combined with chemotherapy in the first-line treatment of advanced or metastatic esophageal carcinoma

Ran QI ; Guiping DU ; Xuting LIU ; Shengnan GAO ; Guoqiang LIU

China Pharmacy 2022;33(12):1466-1473

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 17 , 1/2 Show Home Prev Next End page: GO